date,title,source
Oct-17-18,EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq,Zacks
Oct-18-18,EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting,GlobeNewswire
Oct-29-18,EyePoint Pharmaceuticals Presents Positive YUTIQ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting,GlobeNewswire
Oct-30-18,EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information,GlobeNewswire
Oct-30-18,"EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors",GlobeNewswire
Nov-05-18,EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region,GlobeNewswire
Nov-06-18,EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference,GlobeNewswire
Nov-06-18,"EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates",Zacks
Nov-06-18,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",Benzinga
Nov-06-18,EyePoint Pharmaceuticals: Fiscal 1Q Earnings Snapshot,Associated Press
Nov-06-18,EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments,GlobeNewswire
Nov-12-18,EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU by the Center for Medicare and Medicaid Services (CMS),GlobeNewswire
Nov-27-18,"EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary",GlobeNewswire
Nov-29-18,Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options,Zacks
Dec-17-18,EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index,GlobeNewswire
Jan-03-19,4 Pharma Stocks Raising Eyebrows (1/3/19),ACCESSWIRE
Jan-03-19,EyePoint Pharmaceuticals Provides 2019 Commercial Update,GlobeNewswire
Jan-28-19,"EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors",GlobeNewswire
Jan-30-19,Earnings Preview: EyePoint Pharmaceuticals (EYPT) Q2 Earnings Expected to Decline,Zacks
Feb-04-19,EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg,GlobeNewswire
Feb-13-19,EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility,GlobeNewswire
Feb-14-19,"EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information",GlobeNewswire
Mar-12-19,EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCUTM (dexamethasone intraocular suspension) 9%,GlobeNewswire
Mar-13-19,"The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie",Benzinga
Mar-14-19,EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript,Motley Fool
Mar-14-19,Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT,Thomson Reuters StreetEvents
Mar-14-19,"EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates",Zacks
Mar-14-19,EyePoint Pharmaceuticals: Fiscal 2Q Earnings Snapshot,Associated Press
Mar-14-19,"EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments",GlobeNewswire
Mar-15-19,Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT,Thomson Reuters StreetEvents
Mar-20-19,Edited Transcript of EYPT earnings conference call or presentation 14-Mar-19 12:30pm GMT,Thomson Reuters StreetEvents
Mar-27-19,EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock,GlobeNewswire
Mar-28-19,Here's Why EyePoint Pharmaceuticals Saw Its Share Price Drop Today,Motley Fool
Mar-28-19,EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock,GlobeNewswire
